Abstract
The inheritance of one defective BRCA1 or BRCA2 allele predisposes an individual to developing breast and ovarian cancers. BRCA1 is a multifunctional tumor suppressor protein, which through interaction with a vast array of proteins has implications in processes such as cell cycle, transcription, DNA damage response and chromatin remodeling. Conversely, the oncogene, cyclin D1 is overexpressed in about 35% of all breast cancer cases. In this study, we provide detailed analyses on the phosphorylation state of BRCA1 by cyclin D1/cdk4 complexes. In particular, we have identified Ser 632 of BRCA1 as a cyclin D1/cdk4 phosphorylation site in vitro. Using chromatin immunoprecipitation assays, we observed that the inhibition of cyclin D1/cdk4 activity resulted in increased BRCA1 DNA binding at particular promoters in vivo. In addition, we identified multiple novel genes that are bound by BRCA1 in vivo. Collectively, these results indicate that cyclin D1/cdk4-mediated phosphorylation of BRCA1 inhibits the ability of BRCA1 to be recruited to particular promoters in vivo. Therefore, cyclin D1/Cdk4 phosphorylation of BRCA1 could provide a mechanism to interfere with the DNA-dependent activities of BRCA1.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aubry C, Jenkins PR, Mahale S, Chaudhuri B, Marechal JD, Sutcliffe MJ . (2004). New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity. Chem Commun 15: 1696–1697.
Boulton SJ . (2006). Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 34: 633–645.
Cable PL, Wilson CA, Calzone FJ, Rauscher III FJ, Scully R, Livingston DM et al. (2003). Novel consensus DNA-binding sequence for BRCA1 protein complexes. Mol Carcinog 38: 85–96.
Chen Y, Farmer AA, Chen CF, Jones DC, Chen PL, Lee WH . (1996). BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res 56: 3168–3172.
Coqueret O . (2002). Linking cyclins to transcriptional control. Gene 299: 35–55.
Cortez D, Wang Y, Qin J, Elledge SJ . (1999). Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286: 1162–1166.
de La Fuente C, Santiago F, Chong SY, Deng L, Mayhood T, Fu P et al. (2000). Overexpression of p21(waf1) in human T-cell lymphotropic virus type 1-infected cells and its association with cyclin A/cdk2. J Virol 16: 7270–7283.
Fabbro M, Rodriguez JA, Baer R, Henderson BR . (2002). BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export. J Biol Chem 277: 21315–21324.
Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA et al. (2002). p300 Modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res 62: 141–151.
Hejna M, Schmidinger M, Raderer M . (2002). The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 13: 653–668.
Hillion J, Le Coniat M, Jonveaux P, Berger R, Bernard OA . (1997). AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily. Blood 90: 3714–3719.
Katoh M, Katoh M . (2004). Human FOX gene family. Int J Oncol 25: 1495–1500.
Kehn K, Deng L, de la Fuente C, Strouss K, Wu K, Maddukuri A et al. (2004). The role of cyclin D2 and p21/waf1 in human T-cell leukemia virus type 1 infected cells. Retrovirology 1: 6.
Lacroix M, Leclercq G . (2004). Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83: 249–289.
Lin L, Miller CT, Contreras JI, Prescott MS, Dagenais SL, Wu R et al. (2002). The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res 62: 5273–5279.
Mark WY, Liao JC, Lu Y, Ayed A, Laister R, Szymczyna B et al. (2005). Characterization of segments from the central region of BRCA1: an intrinsically disordered scaffold for multiple protein–protein and protein–DNA interactions? J Mol Biol 345: 275–287.
Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F . (2004). Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430: 226–231.
Moisan A, Gaudreau L . (2006). The BRCA1 COOH-terminal region acts as an RNA polymerase II carboxyl-terminal domain kinase inhibitor that modulates p21WAF1/CIP1 expression. J Biol Chem 281: 21119–21130.
Montminy M, Brindle P, Arias J, Ferreri K, Armstrong R . (1996). Regulation of somatostatin gene transcription by cyclic adenosine monophosphate. Metabolism 45: 4–7.
Mullan PB, Quinn JE, Harkin DP . (2006). The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 25: 5854–5863.
Nakamura T, Furukawa Y, Nakagawa H, Tsunoda T, Ohigashi H, Murata K et al. (2004). Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 23: 2385–2400.
Pao GM, Janknecht R, Ruffner H, Hunter T, Verma IM . (2000). CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci USA 97: 1020–1025.
Paull TT, Cortez D, Bowers B, Elledge SJ, Gellert M . (2001). Direct DNA binding by Brca1. Proc Natl Acad Sci USA 98: 6086–6091.
Rosen EM, Fan S, Ma Y . (2006). BRCA1 regulation of transcription. Cancer Lett 236: 175–185.
Rosen EM, Fan S, Pestell RG, Goldberg ID . (2003). BRCA1 gene in breast cancer. J Cell Physiol 196: 19–41.
Ruffner H, Jiang W, Craig AG, Hunter T, Verma IM . (1999). BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site. Mol Cell Biol 19: 4843–4854.
Santiago F, Clark E, Chong S, Molina C, Mozafari F, Mahieux R et al. (1999). Transcriptional up-regulation of the cyclin D2 gene and acquisition of new cyclin-dependent kinase partners in human T-cell leukemia virus type 1-infected cells. J Virol 73: 9917–9927.
Soni R, Muller L, Furet P, Schoepfer J, Stephan C, Zumstein-Mecker S et al. (2000). Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem Biophys Res Commun 275: 877–884.
Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP, Quinn AG . (2002). FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 62: 4773–4780.
Wang C, Fan S, Li Z, Fu M, Rao M, Ma Y et al. (2005). Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer Res 65: 6557–6567.
Wang H, Shao N, Ding QM, Cui J, Reddy ES, Rao VN . (1997). BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases. Oncogene 15: 143–157.
Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG . (2001). BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci USA 98: 9587–9592.
Acknowledgements
We thank Dr Tanya Paull for the pDC-GST-BRCA1 constructs, Dr Doris German for the cyclin D1 construct and Dr Luke O Dannenberg for critically reviewing this manuscript. K Kehn was supported by a predoctoral research fellowship from the DOD Breast Cancer Research Program (DAMD17-03-1-0198). This work was supported in part by grants from the GWU REF funds to FK and Akos Vertes; Snyder award, and NIH grants AI065236, AI043894 to FK.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Kehn, K., Berro, R., Alhaj, A. et al. Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells. Oncogene 26, 5060–5069 (2007). https://doi.org/10.1038/sj.onc.1210319
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210319
Keywords
This article is cited by
-
Serum anti-SPP1 autoantibody as a potential novel biomarker in detection of esophageal squamous cell carcinoma
BMC Cancer (2022)
-
Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers
BMC Cancer (2015)
-
Cyclin D as a therapeutic target in cancer
Nature Reviews Cancer (2011)
-
Substitution of aspartic acid with glutamic acid at position 67 of the BRCA1 RING domain retains ubiquitin ligase activity and zinc(II) binding with a reduced transition temperature
JBIC Journal of Biological Inorganic Chemistry (2011)
-
The Antiproliferative Effect of EPA in HL60 Cells is Mediated by Alterations in Calcium Homeostasis
Lipids (2009)